A Multi-Center Phase Ib Trial Evaluating the Safety and Efficacy of Lacutamab in Patients With Relapse Peripheral T-Cell Lymphoma That Express KIR3DL2
For more information about the trial above please contact the study team:
Principal Investigator, Irl Greenwell, at email@example.com, or please call +1 843-792-4759.
Study Coordinator, Christina Paskal, at firstname.lastname@example.org.
Trial opened at the following institutions: Medical University of South Carolina